Participant flow

Surgical Debulking of Pituitary Adenomas · Source last updated 2016-08-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Medical therapy with Octreotide LAR 30 mg/month for 3 months preceding surgery Octreotide LAR

   id

   FG000

   title

   Medical Treatment by Octreotide LAR

2. description

   Surgical debulking of pituitary tumor followed by Octreotide LAR if not surgically cured Octreotide LAR transsphenoidal surgery

   id

   FG001

   title

   Surgical Debulking Followed by Octreotide LAR

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         0

      type

      Withdrawal by Subject

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         15

      2. group Id

         FG001

         num Subjects

         26

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         12

      2. group Id

         FG001

         num Subjects

         26

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice